# Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

> **NCT06441747** · PHASE2 · RECRUITING · sponsor: **Australasian Gastro-Intestinal Trials Group** · enrollment: 40 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT06441747
- **Lead sponsor:** Australasian Gastro-Intestinal Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2026-08
- **Final completion:** 2028-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441747, "Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06441747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*